The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1513
Issue 1513
Lixisenatide for Type 2 Diabetes; Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC; Inflectra - An Infliximab Biosimilar; Yosprala - A Combination of Aspirin and Omeprazole; Drug Interaction: Dabigatran (Pradaxa) and Statins; Corrections; Comparison Chart of SGLT2 Inhibitors (online only)
The full issue is available to subscribers Subscriber Login   
Lixisenatide for Type 2 Diabetes

The FDA has approved lixisenatide (Sanofi), a short-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-daily treatment of adults with type 2 diabetes, both alone (Adlyxin) and in a fixed-ratio combination with insulin glargine (Soliqua 100/33). Lixisenatide has been available since 2013 in many other countries as Lyxumia. It is the fifth GLP-1 receptor agonist to be approved in the US.

GLP-1 RECEPTOR AGONISTS — GLP-1 receptor agonists lower glucose levels by potentiating glucose-dependent secretion of insulin, suppressing postprandial glucagon secretion, slowing gastric emptying, and promoting satiety. They lower glycated hemoglobin (A1C) by about 1-1.5%, have been associated with average weight loss of 1.5-2.8 kg, and rarely cause hypoglycemia.1 The GLP-1 receptor agonist liraglutide (Victoza) has been shown ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1513
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35